CARLSBAD, Calif., July 10, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced positive topline, 85-week data from the Phase 3 NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). Ionis and AstraZeneca's eplontersen continued to show sustained improvements in measures of neuropathy disease and a favorable safety and tolerability profile.
Read more at prnewswire.comEplontersen continued to show improvement in ATTRv-PN through 85 weeks
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.